Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

In vitro and in vivo MMP gene expression localisation by In Situ-RT-PCR in cell culture and paraffin embedded human breast cancer cell line xenografts

Authors: Larisa M Haupt, Erik W Thompson, Ann EO Trezise, Rachel E Irving, Michael G Irving, Lyn R Griffiths

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Members of the matrix metalloproteinase (MMP) family of proteases are required for the degradation of the basement membrane and extracellular matrix in both normal and pathological conditions. In vitro, MT1-MMP (MMP-14, membrane type-1-MMP) expression is higher in more invasive human breast cancer (HBC) cell lines, whilst in vivo its expression has been associated with the stroma surrounding breast tumours. MMP-1 (interstitial collagenase) has been associated with MDA-MB-231 invasion in vitro, while MMP-3 (stromelysin-1) has been localised around invasive cells of breast tumours in vivo. As MMPs are not stored intracellularly, the ability to localise their expression to their cells of origin is difficult.

Methods

We utilised the unique in situ-reverse transcription-polymerase chain reaction (IS-RT-PCR) methodology to localise the in vitro and in vivo gene expression of MT1-MMP, MMP-1 and MMP-3 in human breast cancer. In vitro, MMP induction was examined in the MDA-MB-231 and MCF-7 HBC cell lines following exposure to Concanavalin A (Con A). In vivo, we examined their expression in archival paraffin embedded xenografts derived from a range of HBC cell lines of varied invasive and metastatic potential. Mouse xenografts are heterogenous, containing neoplastic human parenchyma with mouse stroma and vasculature and provide a reproducible in vivo model system correlated to the human disease state.

Results

In vitro, exposure to Con A increased MT1-MMP gene expression in MDA-MB-231 cells and decreased MT1-MMP gene expression in MCF-7 cells. MMP-1 and MMP-3 gene expression remained unchanged in both cell lines. In vivo, stromal cells recruited into each xenograft demonstrated differences in localised levels of MMP gene expression. Specifically, MDA-MB-231, MDA-MB-435 and Hs578T HBC cell lines are able to influence MMP gene expression in the surrounding stroma.

Conclusion

We have demonstrated the applicability and sensitivity of IS-RT-PCR for the examination of MMP gene expression both in vitro and in vivo. Induction of MMP gene expression in both the epithelial tumour cells and surrounding stromal cells is associated with increased metastatic potential. Our data demonstrate the contribution of the stroma to epithelial MMP gene expression, and highlight the complexity of the role of MMPs in the stromal-epithelial interactions within breast carcinoma.
Appendix
Available only for authorised users
Literature
1.
Elston CW, Ellis IO, Pinder SE: Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol. 1999, 31: 209-23.CrossRefPubMed
2.
Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000, 10: 415-33. 10.1006/scbi.2000.0379.CrossRefPubMed
3.
Brinckerhoff CE, Rutter JL, Benbow U: Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000, 6: 4823-30.PubMed
4.
Reno F, Sabbatini M, Stella M, Magliacani G, Cannas M: Effect of in vitro mechanical compression on Epilysin (matrix metalloproteinase-28) expression in hypertrophic scars. Wound Repair Regen. 2005, 13: 255-61. 10.1111/j.1067-1927.2005.130307.x.CrossRefPubMed
5.
Chung KF: Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2001, 34: 50s-59s. 10.1183/09031936.01.00229701.CrossRefPubMed
6.
Sato H, Seiki M: Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem (Tokyo). 1996, 119: 209-15.CrossRef
7.
Ries C, Petrides PE: Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe Seyler. 1995, 376: 345-55.PubMed
8.
Lochter A, Sternlicht MD, Werb Z, Bissell MJ: The significance of matrix metalloproteinases during early stages of tumor progression. Ann N Y Acad Sci. 1998, 857: 180-93. 10.1111/j.1749-6632.1998.tb10116.x.CrossRefPubMed
9.
Woessner JF: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. Faseb J. 1991, 5: 2145-54.PubMed
10.
Osteen KG, Rodgers WH, Gaire M, Hargrove JT, Gorstein F, Matrisian LM: Stromal-epithelial interaction mediates steroidal regulation of metalloproteinase expression in human endometrium. Proc Natl Acad Sci USA. 1994, 91: 10129-33.CrossRefPubMedPubMedCentral
11.
Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P: Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA. 1995, 92: 2730-4.CrossRefPubMedPubMedCentral
12.
Pulyaeva H, Bueno J, Polette M, Birembaut P, Sato H, Seiki M, Thompson EW: MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis. 1997, 15: 111-20. 10.1023/A:1018444609098.CrossRefPubMed
13.
Lafleur MA, Drew AF, de Sousa EL, Blick T, Bills M, Walker EC, Williams ED, Waltham M, Thompson EW: Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13. Int J Cancer. 2005, 114: 544-54. 10.1002/ijc.20763.CrossRefPubMed
14.
Yu M, Sato H, Seiki M, Spiegel S, Thompson EW: Elevated cyclic AMP suppresses ConA-induced MT1-MMP expression in MDA-MB-231 human breast cancer cells. Clin Exp Metastasis. 1998, 16: 185-91. 10.1023/A:1006580406314.CrossRefPubMed
15.
Yu M, Sato H, Seiki M, Thompson EW: Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB- 231 human breast cancer cells. Cancer Res. 1995, 55: 3272-7.PubMed
16.
Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J: Mechanisms for pro matrix metalloproteinase activation. Apmis. 1999, 107: 38-44.CrossRefPubMed
17.
McDonnell S, Matrisian LM: Stromelysin in tumor progression and metastasis. Cancer Metastasis Rev. 1990, 9: 305-19. 10.1007/BF00049521.CrossRefPubMed
18.
Benbow U, Rutter JL, Lowrey CH, Brinckerhoff CE: Transcriptional repression of the human collagenase-1 (MMP-1) gene in MDA231 breast cancer cells by all-trans-retinoic acid requires distal regions of the promoter. Br J Cancer. 1999, 79: 221-8.CrossRefPubMedPubMedCentral
19.
Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990, 348: 699-704. 10.1038/348699a0.CrossRefPubMed
20.
Bruner KL, Rodgers WH, Gold LI, Korc M, Hargrove JT, Matrisian LM, Osteen KG: Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. PNAS. 1995, 92: 7362-7366.CrossRefPubMedPubMedCentral
21.
Haupt LM, Thompson EW, Griffiths LR, Irving MG: IS-RT-PCR assay detection of MT-MMP in a human breast cancer cell line. Biochem Mol Biol Int. 1996, 39: 553-61.PubMed
22.
Azzam HS, Arand G, Lippman ME, Thompson EW: Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst. 1993, 85: 1758-64.CrossRefPubMed
23.
Malkinson AM: Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer. 2001, 32: 265-79. 10.1016/S0169-5002(00)00232-4.CrossRefPubMed
24.
25.
Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, et al: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol. 1992, 150: 534-44. 10.1002/jcp.1041500314.CrossRefPubMed
26.
Trezise AE, Linder CC, Grieger D, Thompson EW, Meunier H, Griswold MD, Buchwald M: CFTR expression is regulated during both the cycle of the seminiferous epithelium and the oestrous cycle of rodents. Nat Genet. 1993, 3: 157-64. 10.1038/ng0293-157.CrossRefPubMed
27.
Liotta LA, Stetler-Stevenson W: Metalloproteinases and malignant conversion: does correlation imply causality?. J Natl Cancer Inst. 1989, 81: 556-7.CrossRefPubMed
28.
Curran S, Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000, 36: 1621-30. 10.1016/S0959-8049(00)00156-8.CrossRefPubMed
29.
Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89: 1260-70. 10.1093/jnci/89.17.1260.CrossRefPubMed
30.
Tryggvason K, Hoyhtya M, Pyke C: Type IV collagenases in invasive tumors. Breast Cancer Res Treat. 1993, 24: 209-18. 10.1007/BF01833261.CrossRefPubMed
31.
Bachmeier BE, Vene R, Iancu CM, Pfeffer U, Mayer B, Noonan D, Albini A, Jochum M, Nerlich AG: Transcriptional control of cell density dependent regulation of matrix metalloproteinase and TIMP expression in breast cancer cell lines. Thromb Haemost. 2005, 93: 761-9.PubMed
32.
Kousidou OC, Roussidis AE, Theocharis AD, Karamanos NK: Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential. Anticancer Res. 2004, 24: 4025-30.PubMed
33.
Bachmeier BE, Albini A, Vene R, Benelli R, Noonan D, Weigert C, Weiler C, Lichtinghagen R, Jochum M, Nerlich AG: Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines. Exp Cell Res. 2005, 30: 83-98. 10.1016/j.yexcr.2004.12.019.CrossRef
34.
Gilles C, Polette M, Seiki M, Birembaut P, Thompson EW: Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest. 1997, 76: 651-60.PubMed
35.
Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, Strongin AY: MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res. 2001, 263: 209-23. 10.1006/excr.2000.5118.CrossRefPubMed
36.
Gilles C, Polette M, Coraux C, Tournier JM, Meneguzzi G, Munaut C, Volders L, Rousselle P, Birembaut P, Foidart JM: Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. J Cell Sci. 2001, 114: 2967-76.PubMedPubMedCentral
37.
Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A: Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res. 1998, 58: 3743-50.PubMed
38.
Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY: Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer. 2000, 86: 15-23. 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B.CrossRefPubMed
39.
Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM, Noel A: MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. Faseb J. 2002, 16: 555-64. 10.1096/fj.01-0790com.CrossRefPubMed
40.
Deryugina EI, Soroceanu L, Strongin AY: Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res. 2002, 62: 580-8.PubMed
41.
Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res. 1987, 47: 4355-60.PubMed
42.
Ha HY, Moon HB, Nam MS, Lee JW, Ryoo ZY, Lee TH, Lee KK, So BJ, Sato H, Seiki M, Yu DY: Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res. 2001, 61: 984-90.PubMed
43.
Shimada T, Nakamura H, Yamashita K, Kawata R, Murakami Y, Fujimoto N, Sato H, Seiki M, Okada Y: Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis. Clin Exp Metastasis. 2000, 18: 179-88. 10.1023/A:1006749501682.CrossRefPubMed
44.
Polette M, Clavel C, Birembaut P, De Clerck YA: Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. Pathol Res Pract. 1993, 189: 1052-7.CrossRefPubMed
45.
Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH: Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996, 149: 273-82.PubMedPubMedCentral
46.
Dalberg K, Eriksson E, Enberg U, Kjellman M, Backdahl M: Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg. 2000, 24: 334-40. 10.1007/s002689910053.CrossRefPubMed
47.
Ishigaki S, Toi M, Ueno T, Matsumoto H, Muta M, Koike M, Seiki M: Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. Jpn J Cancer Res. 1999, 90: 516-22.CrossRefPubMed
48.
Bisson C, Blacher S, Polette M, Blanc JF, Kebers F, Desreux J, Tetu B, Rosenbaum J, Foidart JM, Birembaut P, Noel A: Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer. 2003, 105: 7-13. 10.1002/ijc.11012.CrossRefPubMed
49.
Ross DT, Perou CM: A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers. 2001, 17: 99-109.CrossRefPubMed
50.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-52. 10.1038/35021093.CrossRefPubMed
51.
Gilles C, Polette M, Birembaut P, Brunner N, Thompson EW: Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis. 1997, 15: 519-26. 10.1023/A:1018427027270.CrossRefPubMed
52.
Benbow U, Schoenermark MP, Orndorff KA, Givan AL, Brinckerhoff CE: Human breast cancer cells activate procollagenase-1 and invade type I collagen: invasion is inhibited by all-trans retinoic acid. Clin Exp Metastasis. 1999, 17: 231-8. 10.1023/A:1006639214618.CrossRefPubMed
53.
Barrett JM, Puglia MA, Singh G, Tozer RG: Expression of Ets-related transcription factors and matrix metalloproteinase genes in human breast cancer cells. Breast Cancer Res Treat. 2002, 72: 227-32. 10.1023/A:1014993006190.CrossRefPubMed
54.
Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP: Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res. 2001, 21: 3821-8.PubMed
55.
Balduyck M, Zerimech F, Gouyer V, Lemaire R, Hemon B, Grard G, Thiebaut C, Lemaire V, Dacquembronne E, Duhem T, Lebrun A, Dejonghe MJ, Huet G: Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis. 2000, 18: 171-8. 10.1023/A:1006762425323.CrossRefPubMed
56.
Huttenlocher A, Werb Z, Tremble P, Huhtala P, Rosenberg L, Damsky CH: Decorin regulates collagenase gene expression in fibroblasts adhering to vitronectin. Matrix Biol. 1996, 15: 239-50. 10.1016/S0945-053X(96)90115-8.CrossRefPubMed
57.
Behrens P, Rothe M, Wellmann A, Krischler J, Wernert N: The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol. 2001, 194: 43-50. 10.1002/path.844.CrossRefPubMed
58.
Brummer O, Athar S, Riethdorf L, Loning T, Herbst H: Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch. 1999, 435: 566-73. 10.1007/s004280050442.CrossRefPubMed
59.
Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A, Davaris PS: Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol. 1999, 30: 436-42. 10.1016/S0046-8177(99)90120-X.CrossRefPubMed
60.
Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S, Birembaut P: Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem. 1999, 47: 1575-80.CrossRefPubMed
61.
Werb Z, Ashkenas J, MacAuley A, Wiesen JF: Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis. Braz J Med Biol Res. 1996, 29: 1087-97.PubMed
62.
Lochter A, Werb Z, Bissell MJ: Transcriptional regulation of stromelysin-1 gene expression is altered during progression of mouse mammary epithelial cells from functionally normal to malignant. Matrix Biol. 1999, 18: 455-67. 10.1016/S0945-053X(99)00036-0.CrossRefPubMedPubMedCentral
63.
Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 1999, 98: 137-46. 10.1016/S0092-8674(00)81009-0.CrossRefPubMedPubMedCentral
64.
Lebeau A, Nerlich AG, Sauer U, Lichtinghagen R, Lohrs U: Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. Anticancer Res. 1999, 19: 4257-64.PubMed
65.
Ioachim EE, Athanassiadou SE, Kamina S, Carassavoglou K, Agnantis NJ: Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices. Anticancer Res. 1998, 18: 1665-70.PubMed
66.
Bodey B, Bodey B, Siegel SE, Kaiser HE: Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas. Anticancer Res. 2001, 21: 2021-8.PubMed
67.
Cao J, Sato H, Takino T, Seiki M: The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem. 1995, 270: 801-5. 10.1074/jbc.270.2.801.CrossRefPubMed
68.
Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, Bissell MJ, Ronnov-Jessen L: Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol. 2003, 162: 391-402.CrossRefPubMedPubMedCentral
Metadata
Title
In vitro and in vivo MMP gene expression localisation by In Situ-RT-PCR in cell culture and paraffin embedded human breast cancer cell line xenografts
Authors
Larisa M Haupt
Erik W Thompson
Ann EO Trezise
Rachel E Irving
Michael G Irving
Lyn R Griffiths
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-18

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers

Research article

Identification of genes regulated by Wnt/β-catenin pathway and involved in apoptosis via microarray analysis

Research article

Genetic polymorphisms of MMP1, MMP3 and MMP7gene promoter and risk of colorectal adenoma

Research article

Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients

Research article

Relationship between cyclooxygenase 8473T>Cpolymorphism and the risk of lung cancer: a case-control study

Research article

Mismatch repair and treatment resistance in ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits